University of Notre Dame du Lac’s Clovis Oncology, Inc. CLVS Stock Holding History

University of Notre Dame du Lac’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-101,386	Closed	-$2.52M	–	75
2019 Q1	$2.52M	Sell	101,386 -38,183	-27%	-$957K	0.56%	54
2018 Q4	$2.51M	Buy	139,569 +59,128	+74%	+$1.21M	0.61%	46
2018 Q3	$2.36M	Buy	80,441 +26,244	+48%	+$1.02M	0.44%	66
2018 Q2	$2.46M	Buy	54,197 +10,436	+24%	+$508K	0.48%	60
2018 Q1	$2.31M	Buy	43,761 +3,772	+9%	+$220K	0.43%	69
2017 Q4	$2.72M	Buy	39,989 +3,460	+9%	+$242K	0.56%	59
2017 Q3	$3.01M	Sell	36,529 -14,366	-28%	-$1.14M	0.84%	55
2017 Q2	$4.76M	Buy	50,895 +9,270	+22%	+$567K	1.41%	17
2017 Q1	$2.65M	Buy	+41,625	New	+$2.53M	0.66%	54

Other funds holding CLVS

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

University of Notre Dame du Lac's CLVS Position: Q2 2019 in Review

University of Notre Dame du Lac sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 101,386 shares — an estimated $2.52M sold.

University of Notre Dame du Lac first reported a position in CLVS in Q1 2017 and held it in 9 quarters. The position peaked at $4.76M in Q2 2017. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

University of Notre Dame du Lac reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
University of Notre Dame du Lac sold 101,386 Clovis Oncology, Inc. shares in Q2 2019, an estimated $2.52M.
University of Notre Dame du Lac first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 9 quarters.
University of Notre Dame du Lac's Clovis Oncology, Inc. position peaked at $4.76M in Q2 2017.
167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on University of Notre Dame du Lac's 13F filing for Q2 2019, filed 14 Aug 2019.